Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Ardea Biosciences, Inc.
Ardea Biosciences Announces Progress of Clinical Development Programs and Reports Third Quarter and Year-to-Date 2008 Financial Results
December 2nd, 2008
Ardea Biosciences, Inc. (Nasdaq: RDEA), a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of human immunodeficiency virus (HIV), gout, cancer and inflammatory diseases, reported on recent accomplishments and financial results for the three and nine months ended September 30, 2008. "We have continued to make significant progress since providing our second quarter 2008 update. In August, we initiated a Phase 1 study in normal healthy volunteers of RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, and recently reported positive preliminary results from that trial, including a...
Source: Cancer Weekly (2008-12-02)
|
